Id |
Subject |
Object |
Predicate |
Lexical cue |
T581 |
0-129 |
Sentence |
denotes |
Contrary to B cell activation, some studies have shown lower antibody durability in both mild and severe cases (Yu et al., 2020). |
T582 |
130-284 |
Sentence |
denotes |
In a longitudinal study on a 26-year-old woman with a moderate disease condition, antibody response disappeared within three months (Liu A. et al., 2020). |
T583 |
285-486 |
Sentence |
denotes |
In a sizable cohort of samples, asymptomatic patients (n = 37 with median age 41 years) had relatively lower durability of the IgG and IgM antibodies in comparison to the symptomatic patients (n = 37). |
T584 |
487-600 |
Sentence |
denotes |
Further, the viral shedding in the asymptomatic group was higher than the symptomatic group (Long et al., 2020b). |
T585 |
601-803 |
Sentence |
denotes |
Similarly, Ibarrondo et al. has shown the same antibody durability in 34 COVID-19 patients with a mean age of 43 years when studied longitudinally for a period of upto 4 months (Ibarrondo et al., 2020). |
T586 |
804-925 |
Sentence |
denotes |
The authors found a significant decline in IgG antibodies in the sera of convalescent patients with mostly mild symptoms. |
T587 |
926-1091 |
Sentence |
denotes |
A declining trend was seen for multiple SARS-CoV-2 antibodies like IgG N, IgM, IgG S1, and IgA S1 in the longitudinal analysis (n = 487) (Gudbjartsson et al., 2020). |
T588 |
1092-1243 |
Sentence |
denotes |
In another longitudinal study, the disappearance of S and N protein-specific antibodies was observed within 3 months of recovery (Liu A. et al., 2020). |
T589 |
1244-1572 |
Sentence |
denotes |
Based on these reports, we can infer that the antibody response in some COVID-19 patients may not be long-lasting, which poses a challenge for antibody-based therapy and vaccine research—further, these data caution towards chances of reinfection, as shown to be the case with other seasonal coronaviruses (Edridge et al., 2020). |
T590 |
1573-1711 |
Sentence |
denotes |
However, larger cohort size and longer time frame longitudinal studies are needed to find the durability of antibody response in COVID-19. |